Healthcare / BiotechnologyNasdaqGM
$13.02
-0.11 (-0.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-395.9M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-61.5%
↓Gross Margin
N/A
•Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-585.0%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $67.7M · net income $-412.7M · FCF $-395.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $67.7M | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M | — |
| Net Income | $-412.7M | $-412.7M | $-519.0M | $-481.2M | $-474.2M | $-267.9M | $-134.2M | $-474.2M | $-85.3M | $-67.5M | $-31.6M | $-12.4M |
| EBITDA | $-425.1M | $-425.1M | $-524.0M | $-506.3M | $-450.6M | $-261.0M | $-130.3M | $-100.8M | $-86.4M | $-66.6M | $-31.1M | $-13.1M |
| EPS | -3.81 | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | — | — | — | — | — |
| Operating Margin | -651.7% | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | -266.3% | -195.2% | — |
| Net Margin | -609.9% | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -1100.1% | -280.4% | -258.6% | -192.0% | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.14 | 0.14 | 0.24 | 0.11 | 0.11 | — | — | — | — | — | — | — |
| Current Ratio | 6.10 | 6.10 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-395.9M | $-395.9M | $-354.7M | $-408.1M | $-391.7M | $-237.8M | $-53.5M | $-110.0M | $-67.6M | $-75.4M | $29.9M | — |
| Returns | ||||||||||||
| ROE | -61.5% | -61.5% | -59.5% | -45.8% | -38.4% | -25.8% | -25.5% | -175.7% | -30.7% | -22.5% | -15.1% | 58.5% |
| Valuation | ||||||||||||
| P/B | 2.10 | 2.10 | 1.38 | 2.42 | 2.37 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | 16.9% | 16.9% | 59.6% | -30.4% | — | -43.0% | 34.5% | 41.6% | 16.5% | 58.5% | — | — |
| EPS Growth | 27.4% | 27.4% | 3.1% | 12.0% | — | -57.5% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+69.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.25 → -3.81
Residual
+69.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.